LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Dihydroorotate dehydrogenase inhibitors in SARS‐CoV‐2 infection

Photo by bermixstudio from unsplash

Since late 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral outbreak has spread all over the world. The disease caused by SARS-CoV-2, named COVID-19, has caused over 550,000… Click to show full abstract

Since late 2019, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral outbreak has spread all over the world. The disease caused by SARS-CoV-2, named COVID-19, has caused over 550,000 deaths and infected close to 13,000,000 people worldwide (by Jul 12). Although individuals from all ages can be infected, the clinical prognosis is worse for patients harboring one or more risk factors, including age, obesity, hypertension, diabetes, respiratory and/or cardiovascular disease, and cancer, or auto-immune diseases, among others.

Keywords: dehydrogenase inhibitors; inhibitors sars; sars cov; cov infection; dihydroorotate dehydrogenase

Journal Title: European Journal of Clinical Investigation
Year Published: 2020

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.